26.17
price up icon3.77%   0.95
pre-market  Pre-market:  26.18   0.010   +0.04%
loading
Immunovant Inc stock is traded at $26.17, with a volume of 993.95K. It is up +3.77% in the last 24 hours and down -11.20% over the past month. Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
See More
Previous Close:
$25.22
Open:
$25.37
24h Volume:
993.95K
Relative Volume:
1.13
Market Cap:
$3.84B
Revenue:
-
Net Income/Loss:
$-272.55M
P/E Ratio:
-13.56
EPS:
-1.93
Net Cash Flow:
$-243.55M
1W Performance:
-9.45%
1M Performance:
-11.20%
6M Performance:
-15.23%
1Y Performance:
-22.57%
1-Day Range:
Value
$24.87
$26.22
1-Week Range:
Value
$24.61
$28.99
52-Week Range:
Value
$24.61
$45.58

Immunovant Inc Stock (IMVT) Company Profile

Name
Name
Immunovant Inc
Name
Phone
917-580-3099
Name
Address
320 WEST 37TH STREET, NEW YORK, NY
Name
Employee
207
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
IMVT's Discussions on Twitter

Compare IMVT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
IMVT 26.17 3.84B 0 -272.55M -243.55M -1.93
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-15-24 Initiated Wolfe Research Outperform
Dec-12-23 Initiated Deutsche Bank Buy
Oct-13-23 Upgrade UBS Neutral → Buy
Sep-26-23 Upgrade Raymond James Mkt Perform → Outperform
May-01-23 Initiated BofA Securities Buy
Apr-25-23 Initiated Citigroup Buy
Mar-31-23 Initiated Piper Sandler Overweight
Mar-30-23 Initiated Stifel Buy
Feb-15-23 Initiated Cantor Fitzgerald Overweight
Feb-13-23 Upgrade Guggenheim Neutral → Buy
Jan-03-23 Upgrade Wells Fargo Equal Weight → Overweight
Sep-26-22 Downgrade UBS Buy → Neutral
Dec-08-21 Initiated Wells Fargo Equal Weight
Aug-03-21 Downgrade Robert W. Baird Outperform → Neutral
Aug-02-21 Downgrade Credit Suisse Neutral → Underperform
Jun-01-21 Downgrade Guggenheim Buy → Neutral
Jun-01-21 Downgrade Stifel Buy → Hold
Oct-28-20 Initiated UBS Buy
Oct-12-20 Initiated Guggenheim Buy
Oct-08-20 Initiated Stifel Buy
Oct-02-20 Initiated Credit Suisse Outperform
Aug-26-20 Reiterated H.C. Wainwright Buy
Aug-25-20 Initiated Raymond James Outperform
Jul-29-20 Initiated H.C. Wainwright Buy
Feb-24-20 Initiated SVB Leerink Outperform
View All

Immunovant Inc Stock (IMVT) Latest News

pulisher
Nov 20, 2024

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Immunovant stock hits 52-week low at $24.66 amid market shifts - Investing.com Nigeria

Nov 20, 2024
pulisher
Nov 13, 2024

Principal Financial Group Inc. Purchases 391,436 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

(IMVT) Technical Data - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC's Strategic Acquisition of Immunovant Inc Shares - GuruFocus.com

Nov 13, 2024
pulisher
Nov 11, 2024

Immunovant: Pipeline Progressing With One Minor Delay (NASDAQ:IMVT) - Seeking Alpha

Nov 11, 2024
pulisher
Nov 09, 2024

Immunovant (NASDAQ:IMVT) Posts Earnings Results, Misses Expectations By $0.15 EPS - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Analysts Provide An Important Insights On Immunovant Inc (IMVT) - Stocks Register

Nov 09, 2024
pulisher
Nov 08, 2024

Immunovant’s Strategic Advances in Autoimmune Therapies - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

Interesting IMVT Put And Call Options For March 2025 - Nasdaq

Nov 08, 2024
pulisher
Nov 08, 2024

Immunovant's (IMVT) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Immunovant Inc (IMVT) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses | IMVT Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

Immunovant Breaks Above 200-Day Moving AverageBullish for IMVT - Nasdaq

Nov 06, 2024
pulisher
Nov 04, 2024

Emerald Mutual Fund Advisers Trust Has $5.24 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Where are the Opportunities in (IMVT) - Stock Traders Daily

Nov 02, 2024
pulisher
Nov 02, 2024

Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - Defense World

Nov 02, 2024
pulisher
Nov 02, 2024

Immunovant, Inc. (NASDAQ:IMVT) Position Boosted by abrdn plc - MarketBeat

Nov 02, 2024
pulisher
Oct 30, 2024

Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - The Manila Times

Oct 29, 2024
pulisher
Oct 29, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - ForexTV.com

Oct 29, 2024
pulisher
Oct 26, 2024

Immunovant's chief medical officer sells $94,171 in stock By Investing.com - Investing.com Canada

Oct 26, 2024
pulisher
Oct 25, 2024

Immunovant CTO Jay Stout sells $80,912 in stock By Investing.com - Investing.com Canada

Oct 25, 2024
pulisher
Oct 25, 2024

Immunovant, Inc. (NASDAQ:IMVT) CTO Sells $80,912.20 in Stock - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Immunovant CTO Jay Stout sells $80,912 in stock - Investing.com India

Oct 25, 2024
pulisher
Oct 25, 2024

Immunovant's chief medical officer sells $94,171 in stock - Investing.com India

Oct 25, 2024
pulisher
Oct 25, 2024

Immunovant's chief legal officer Mark Levine sells shares worth $128,780 By Investing.com - Investing.com Australia

Oct 25, 2024
pulisher
Oct 25, 2024

Immunovant's chief legal officer Mark Levine sells shares worth $128,780 - Investing.com

Oct 25, 2024
pulisher
Oct 19, 2024

Immunovant CFO Eva Renee Barnett sells $94,172 in stock By Investing.com - Investing.com Australia

Oct 19, 2024
pulisher
Oct 19, 2024

Immunovant's chief medical officer William Macias sells $91,782 in stock - Investing.com India

Oct 19, 2024
pulisher
Oct 19, 2024

Immunovant's chief legal officer sells $82,339 in stock By Investing.com - Investing.com Australia

Oct 19, 2024
pulisher
Oct 19, 2024

Immunovant's chief legal officer sells $82,339 in stock - Investing.com India

Oct 19, 2024
pulisher
Oct 19, 2024

Exchange Traded Concepts LLC Buys 9,438 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Oct 19, 2024
pulisher
Oct 19, 2024

Immunovant CFO Eva Renee Barnett sells $94,172 in stock - Investing.com

Oct 19, 2024
pulisher
Oct 19, 2024

Immunovant CEO Peter Salzmann sells $261,845 in shares By Investing.com - Investing.com Australia

Oct 19, 2024
pulisher
Oct 18, 2024

Immunovant CEO Peter Salzmann sells $261,845 in shares - Investing.com

Oct 18, 2024
pulisher
Oct 18, 2024

Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $91,782.52 in Stock - MarketBeat

Oct 18, 2024
pulisher
Oct 16, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Oct 16, 2024
pulisher
Oct 16, 2024

IMVT (Immunovant Inc) has impressive results - US Post News

Oct 16, 2024
pulisher
Oct 15, 2024

Raymond James gives an Outperform recommendation for Immunovant Inc (IMVT) - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Analyzing Ratios: Immunovant Inc (IMVT)’s Financial Story Unveiled - The Dwinnex

Oct 15, 2024
pulisher
Oct 14, 2024

Immunovant: Switching Lead Candidates Increases Risk (NASDAQ:IMVT) - Seeking Alpha

Oct 14, 2024

Immunovant Inc Stock (IMVT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):